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The liver harbors a distinct capacity for endogenous
regeneration; however, liver regeneration is often
impaired in disease and therefore insufficient to
compensate for the loss of hepatocytes and organ
function. Here we describe a functional genetic
approach for the identification of gene targets that
can be exploited to increase the regenerative capac-
ity of hepatocytes. Pools of small hairpin RNAs
(shRNAs) were directly and stably delivered into
mouse livers to screen for genes modulating liver
regeneration. Our studies identify the dual-specific
kinase MKK4 as a master regulator of liver regenera-
tion. MKK4 silencing robustly increased the regener-
ative capacity of hepatocytes in mouse models of
liver regeneration and acute and chronic liver failure.
Mechanistically, induction of MKK7 and a JNK1-
dependent activation of the AP1 transcription factor
ATF2 and the Ets factor ELK1 are crucial for
increased regeneration of hepatocytes with MKK4
silencing.
INTRODUCTION
Impaired organ functionality due to aging or disease represents a
major cause of death in humans. Various metazoa such as
planarian or axolotl (Sa´nchez Alvarado and Tsonis, 2006;
McCusker and Gardiner, 2011) harbor the capacity for endoge-
nous tissue regeneration upon loss of whole parts of the body.
Endogenous regeneration in metazoans occurs either via
locally differentiating, but nondividing, stem cells (morphallaxis)
or via dedifferentiation and expansion of differentiated cells at
the site of damage or loss of tissue (epimorphosis) (Poss et al.,2003). In contrast to lower metazoa species, the ability for
endogenous tissue regeneration is limited in mammals, with
one prominent exception, the liver. The liver harbors an enor-
mous regenerative capacity, whereas in mice full liver mass
and function can be restored within less than 2 weeks of surgical
removal of up to two-thirds of the liver or after toxic liver damage.
Liver regeneration can be seen as an example for epimorphosis,
since differentiated hepatocytes residing in the G0 phase of
the cell cycle re-enter the cell cycle to give rise to new hepato-
cytes (Michalopoulos, 2007).
Despite its distinct intrinsic capacity for endogenous regener-
ation, there are various disease conditions where this capacity is
not sufficient to compensate for the loss of hepatocytes and or-
gan function. In humans and rodents, at least 10%–15% intact
livermass is needed tomaintain the liver’s homeostatic functions
and for recovery from liver damage (Gaub and Iversen, 1984;
Starzl et al., 1975). Any acute or chronic liver damage leading
to a more profound liver damage ultimately results in fatal acute
or chronic liver failure. While acute liver failure is relatively rare,
chronic liver failure with associated development of liver fibrosis,
and finally cirrhosis, is associated with one million deaths each
year (World Health Organization, 2011). Persistent viral infections
with hepatitis B (HBV) (Lok andMcMahon, 2009) or C virus (HCV)
(Shepard et al., 2005) are the major causes for chronic liver dam-
age and liver cirrhosis. However, the number of patients suffering
from chronic liver damage due to alcohol abuse or from nonalco-
holic fatty liver disease (NAFLD), as a result of malnutrition or
metabolic disease such as diabetes, is steadily increasing.
Despite the fact that hepatocytes harbor a nearly infinite
capacity to proliferate in vivo, as shown by serial transplantation
experiments (Overturf et al., 1997a), regeneration defects
encountered in liver diseases make liver transplantation the
only definitive treatment option for fulminant acute liver failure
and end-stage chronic liver disease. The number of donors,
however, is limited and new strategies to increase the regenera-
tive capacity of damaged livers are urgently needed.Cell 153, 389–401, April 11, 2013 ª2013 Elsevier Inc. 389
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We aimed to functionally identify gene targets that can be ex-
ploited to increase the regenerative capacity of hepatocytes. By
screening pools of small hairpin RNAs (shRNAs) directly in
mouse livers in vivo, we identified the dual-specific kinase
MKK4 as a master regulator of liver regeneration. MKK4
suppression significantly increased the regenerative capacity
of hepatocytes in mouse models of liver repopulation and regen-
eration and showed marked therapeutic efficacy in disease
models of acute and chronic liver failure. Strikingly, MKK4
suppression in hepatocytes reduced fibrosis after chronic liver
damage. Hepatocytes with stable RNA interference (RNAi)-
mediated MKK4 silencing show faster cell-cycle entry and
progression during liver regeneration, dependent on an upregu-
lation of MKK7 and JNK1-mediated activation of the AP1
transcription factor ATF2 and the Ets factor ELK1. Our study
identifies and validates MKK4 as a therapeutic target to increase
hepatocyte regeneration and provides one blueprint for func-
tionally identifying gene targets to increase the endogenous
regenerative capacity of tissues.
RESULTS
Stable Repopulation of Mouse Livers with
shRNA-Encoding Transposable Elements
The fumarylacetoacetate hydrolase (FAH) knockout mouse is a
well-established system, wherein FAH/ livers can be selec-
tively repopulated from FAH-expressing hepatocytes (Overturf
et al., 1996). The lethality of mice deficient for FAH, an enzyme
involved in tyrosine catabolism, is prevented by continuous
treatment with the drug nitisinone (NTBC), which blocks the
accumulation of intermediary hepatotoxins (Figure S1) (Grompe
et al., 1995). FAH/ mice undergo liver failure and die shortly
after NTBC withdrawal. In livers of untreated FAH/mice, there
is a strong selection pressure for FAH-expressing hepatocytes
that can be used to repopulate these livers from transplanted
hepatocytes with profound FAH expression or from hepatocytes
after retroviral correction of the FAH gene defect (Overturf
et al., 1996).
We generated transposable elements for stable coexpression
of FAH, green fluorescent protein (GFP) and microRNA-basedFigure 1. Efficient Repopulation of FAH/ Mouse Livers from Hepatoc
(A) Schematic representation of transposable elements for stable intrahepatic ge
microRNA-based shRNAs.
(B) Knockdown analysis of transposon plasmids by western blot for the retinobla
and an expression plasmid for human Rb. Tubulin serves as a loading control. Ex
(C) Body-weight development of mice undergoing liver repopulation after stable (
elements (data are presented as mean ± SD; n = 5 mice per group; red arrow in
(D) Time-course analysis of liver repopulation after stable intrahepatic transfer o
see (A) as determined by GFP imaging on explanted livers or a-FAH immunofluore
liver sections: 200 3 magnification).
(E) Western blot analysis for FAH expression in wild-type (wt) or FAH/ mouse li
as shown in (A). Tubulin serves as a loading control.
(F) In vivo knockdown analysis by bioluminescence imaging of mice with stable
shRNA (shNC) after intrahepatic delivery of a luciferase expression vector (pcDN
(G) Histopathological analysis and TUNEL staining for apoptotic cells on liver sect
treated positive control (shown are representative photographs, n = 5).
(H) Serum transaminase measurements (AST) of mice with stable intrahepatic shR
SD; n = 5). See also Figures S1 and S2.shRNAs (shRNAmir, hereafter referred to as shRNAs) (Chang
et al., 2006) that allow for an efficient suppression of target
gene expression (Figures 1A and 1B). To test whether FAH/
mouse livers could be repopulated from FAH-expressing hepa-
tocytes with stable shRNA expression, we used hydrodynamic
injection (Hickman et al., 1994) to stably deliver transposable el-
ements coexpressing FAH and a nontargeting shRNA (shNC)
together with sleeping beauty transposase (SB13) (Zayed
et al., 2004) into hepatocytes of FAH/ livers (Figure S2A). It
has been shown that effective liver repopulation in FAH/
mice is accompanied by an increase of body weight over time
(Overturf et al., 1997b) and we therefore followed up body weight
development of mice after stable intrahepatic delivery of trans-
posable elements. NTBC was withdrawn 1 day after transposon
delivery. Whereas all mice that had only received the FAH trans-
poson vector without transposase (only transient, short time FAH
expression in hepatocytes) died within 30 days after intrahepatic
delivery (Figure S2B), mice that had received transposable
element plus transposase showed a continuous gain of weight,
regardless of GFP or shRNA coexpression (Figure 1C). In line
with these results, efficient liver replacement from FAH/GFP/
shRNA-expressing hepatocytes was also detected by GFP
imaging (Figure 1D, left panel) on explanted mouse livers or by
a-FAH immunofluorescence stainings on tissue sections from
such livers (Figure 1D, right panel). Furthermore, western blot
analyses of protein lysates from repopulated mouse livers
showed FAH protein levels comparable to C57/Bl6 wild-type
livers (Figure 1E), indicating an efficient expression from the
transposon vector after stable integration into the hepatocyte
genome. Taken together, these data show that FAH/ mouse
livers can be efficiently repopulated from hepatocytes with
stable transposon-mediated FAH and shRNA expression. To
test whether stable shRNA expression results in a sufficient
knockdown of target genes in hepatocytes in vivo, we hydrody-
namically delivered a luciferase expression vector into mouse
livers that had been stably repopulated with an shRNA targeting
luciferase (shLuc) or a nontargeting shRNA (shNC). External
bioluminescence imaging revealed effective suppression of
luciferase activity in shLuc but not in shNC-expressing livers
(Figure 1F).ytes Stably Coexpressing Fumarylacetoacetase and shRNAs
ne expression of FAH, the marker gene green fluorescent protein (GFP), and
stoma (Rb) protein. 293T cells were cotransfected with vectors as shown in (A)
periments were done in triplicates and a representative western blot is shown.
+SB13) or transient intrahepatic gene transfer of FAH-expressing transposable
dicates NTBC withdrawal 1 day post injection; y indicates death of mice).
f transposable elements expressing FAH, GFP, and shNC (p/T-FAHIG-shNC,
scence analysis on liver sections (n = 3; representative photographs are shown;
vers after repopulation from hepatocytes harboring the indicated transposons
intrahepatic expression of an shRNA-targeting luciferase (shLuc) or a control
A.Luc).
ions from repopulated mice (2003magnification). The inset depicts a DNaseI-
NA expression and age-matched control mice (data are represented asmean ±
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It has recently been reported that intrahepatic expression of
stem-loop-stem shRNAs (25-, 23-, 21-mers) delivered by
adeno-associated viruses (AAV) can result in liver toxicity (Grimm
et al., 2006); in line with these data, unpublished data from our
group showed that stable transposon-mediated intrahepatic
delivery of 19-mer stem-loop-stem shRNAs (driven by the U6
promoter) can induce liver toxicity (T.W. and L.Z., unpublished
data). In strong contrast, our results thus far showed efficient
liver repopulation from hepatocytes stably expressing micro-
RNA-based shRNAs (Figures 1C and 1D), without any signs of
liver damage. In support of this observation, histopathological
evaluation and TUNEL staining of mouse livers after stable
repopulation with noncoding shRNAs did not reveal any signs
of liver damage (Figure 1G) and serum levels of liver transami-
nase AST were not found elevated (Figure 1H), thus confirming
that microRNA-based shRNAs are physiological silencing trig-
gers that do not result in liver toxicity. Together, our data show
that FAH/ mouse livers can be efficiently and safely repopu-
lated from hepatocytes stably expressing FAH, GFP, and
shRNAs from transposable elements.
Direct In Vivo RNAi Screening for Genes that Impact
the Endogenous Regenerative Capacity of Hepatocytes
We reasoned that the established systemwould be ideally suited
to conduct direct in vivo RNAi screens for genes that positively or
negatively impact the regenerative capacity of hepatocytes. The
identification of such target genes holds the great promise of
instructing new therapies to increase hepatocyte regeneration
in diseased livers. Because it has been suggested that overlap-
ping signaling pathwaysmight control hepatocyte proliferation in
liver regeneration and liver cancer (reviewed in Teoh, [2009]), we
decided to conduct a screen using a focused pool of 631
shRNAs targeting genes that were found embedded in focal
genomic deletions of 100 human hepatocellular carcinomas
(Zender et al., 2008). The shRNA pool was subcloned into the
p/T-FAHIG transposon vector (see Figure 1A) and hydrodynam-
ically codelivered with an SB13 transposase encoding vector
into the livers of FAH/ mice. To induce liver repopulation
from hepatocytes with stable transposon integration, we took
mice off NTBC. Under these conditions liver repopulation from
hepatocytes with restored FAH expression is initiated and hepa-
tocytes harboring shRNAs conferring a repopulation and regen-
eration advantage will outcompete those harboring neutral
shRNAs or shRNAswhose knockdown even confers a disadvan-
tage during liver repopulation (Figure 2A).
The inflammatory reaction and cytokine milieu in FAH/ livers
after NTBC withdrawal reflects many features of chronically
damaged, regenerating human livers (Grompe et al., 1995), sug-
gesting similar mechanisms of hepatocellular proliferation con-
trol in both settings. Nevertheless, as an additional model for liver
regeneration under chronic damage, we also subjected mice,
after successful liver repopulation with the shRNA library, to re-
petitive carbon tetrachloride (CCl4) treatments (6 weeks), a
well-defined and characterized model of chronic liver damage
that shares many features of chronic liver disease in humans,
including the development of liver fibrosis (Pierce et al., 1987).
To quantify the abundance of each shRNA within the population,
we isolated genomic DNA from individual livers after completion392 Cell 153, 389–401, April 11, 2013 ª2013 Elsevier Inc.of liver repopulation and from livers after CCl4 treatment (Fig-
ure 2A, n = 5 livers for each condition). shRNA cassettes were
PCR amplified from genomic DNA as well as from the initial
transposon shRNA pool and subjected to deep sequencing in
order to quantify potential changes in the abundance of partic-
ular shRNAs during liver repopulation and CCl4-mediated
chronic liver damage. Average values for shRNA representation
in each of the three conditions were calculated and used to
determine the x-fold shRNA enrichment or depletion comparing
repopulated livers and CCl4-treated livers to the library pool (Fig-
ures 2B and 2C). Expectedly, the majority of shRNAs had no
impact on liver regeneration and therefore their frequency did
not increase or decrease compared to the initial representation
in the shRNA library pool (Figures 2B and 2C). However, we
identified several shRNAs that were enriched during liver repo-
pulation and also after CCl4 treatment (Figures 2B and 2C). As
a cutoff criterion for further studies, we chose to select shRNAs
that were R 5-fold positively or negatively regulated in at least
four out of five mice analyzed for each condition.
Overall, out of 631 shRNAs that were screened, 11 shRNAs
fulfilled these criteria in the repopulation group and 10 in the
CCl4 group (Figures 2D and 2E). Strikingly, in both groups we
identified MKK4 as our top-scoring target, with an average
shRNA enrichment of 3,900-fold in the repopulation group and
13,500-fold in the CCl4 group. Because MKK4 is a kinase and
should therefore represent a good drug target, we decided to
follow up on this candidate gene.
RNAi-Mediated Suppression of MKK4 Expression
Enhances the Regenerative Capacity of Hepatocytes
After confirmation of efficient MKK4 knockdown by two indepen-
dent shRNAs (Figures 3A and 3B), we next sought to functionally
validate MKK4 as a target gene to increase liver regeneration.
For this purpose we developed an assay, wherein liver repopula-
tion of FAH/ livers occurs from limited amounts of primarily
transfected hepatocytes (Figure 3C). We hypothesized that
below a certain threshold of stably transfected FAH-expressing
hepatocytes, liver repopulation would not be possible in the
presence of a noncoding shRNA (shNC), whereas hepatocytes
with RNAi-mediated MKK4 knockdown by virtue of their
increased regenerative capacity should still be capable of regen-
erating themouse liver (Figure 3C). Indeed, we found that already
a 10-fold reduction of the amount of hydrodynamically delivered
transposon DNA (2.5 mg) resulted in fatal liver failure due to
insufficient liver repopulation (Figures 3D and S3A), when a non-
targeting shRNA was delivered. In contrast, mice receiving
transposable elements expressing MKK4-shRNAs with an equal
primary transfection efficiency (Figure S3B) not only gained
weight and successfully repopulated their livers under these
conditions (Figures 3D and S3A), but even survived when the
amount of primarily delivered transposon was reduced to one-
twentieth (Figures 3D and S3A). In line with their survival and
the detected gain in body weight over time, we found that
mice having received MKK4-shRNA-encoding transposon
already at day 20 after stable delivery showed 9.9% GFP-
positive, repopulated liver surface, whereas at the same time
point only 1.7% GFP-positive repopulated liver surface was
found in livers that had received transposable elements
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Figure 2. Setup and Results of an In Vivo
RNAi Screen for Liver Regeneration Genes
(A) Schematic outline of the in vivo RNAi screen.
Pools of shRNAs are stably delivered into FAH/
livers via hydrodynamic tail vein injection of
transposable elements (FAHIG-shRNA vector, see
Figure 1A). Livers are efficiently repopulated from
hepatocytes harboring stable transposon expres-
sion. A cohort of mice with fully repopulated
mouse livers was subjected to CCl4 treatment to
induce chronic liver damage and liver regenera-
tion. Hepatocytes with shRNAswhose knockdown
confers an advantage will increase in number
during liver regeneration and/or liver damage
(indicated as black shRNAs) while those harboring
disadvantageous shRNAs will deplete from the
population (indicated by green shRNAs). The fre-
quency of any shRNA in the population is quanti-
fied by deep sequencing.
(B) Enrichment or depletion (log2 scale) of a pool of
631 shRNAs that was screened as described in
Figure 2A. The representation of each shRNA after
repopulation of the liver (2 months after injection)
was compared to its representation in the plasmid
pool. Shown is the corrected mean fold change of
five individually analyzed mice (blue bars).
(C) Enrichment or depletion (log2 scale) of 631
shRNAs that were screened as described in Fig-
ure 2A. Representation of each shRNA after
6 weeks (12 treatments) of CCl4 treatment (red
bars, n = 5) were compared to its representation in
theplasmidpool. Shown is the correctedmean fold
changeof five individually analyzedmice (redbars).
(D) List of shRNAs that showed at least 5-fold
change (positive or negative regulation) in four out
of five analyzed animals after repopulation.
Plotted is the x-fold change of shRNA abundance
compared to the abundance of the respective
shRNA in the library.
(E) List of shRNAs that showed at least 5-fold change (positive or negative regulation) in four out of five analyzed animals after CCl4-mediated chronic liver
damage. Plotted is the x-fold change of shRNA abundance compared to the abundance of the respective shRNA in the library.encoding for a noncoding shRNA (Figures 3E and 3F). Because
we did not detect differences in the number of apoptotic cells
in repopulating shMKK4 livers compared to shNC livers
(Figure S3C), our data suggest that the enhanced repopulation
efficiency of hepatocytes with MKK4 knockdown in this model
system is mainly due to enhanced hepatocyte proliferation.
MKK4 Knockdown Increases Hepatocyte Regeneration
through Faster Cell-Cycle Entry and Progression
Partial hepatectomy is a well-established procedure to induce
synchronized cell-cycle entry of all remaining hepatocytes after
removal of two-thirds of the liver (Grisham, 1962). In order to
analyze the effect ofMKK4 suppression on hepatocyte cell-cycle
entry and progression in this model, we subjected mouse livers
with stable intrahepatic expression of MKK4-shRNAs or non-
coding shRNAs to partial hepatectomy (PH) and prepared
nuclear extracts from the remaining and regenerating liver tissue
at different time points after PH (Figure 4A). Strikingly, MKK4-
shRNA-expressing livers showed a faster cell-cycle entry as indi-
cated by cyclin E expression as early as 24 hr after PH, while in
shNC-expressing livers cyclin E was detectable earliest, 38 hrafter PH (Figure 4B). Cyclin A is required for cell-cycle progres-
sion through S phase and, indicative of a faster cell-cycle
progression in shMKK4 livers, we found strong accumulation
of cyclin A already 48 hr after PH (late S phase and G2 phase),
while only weak cyclin A expression was detectable at 48 hr in
shNC livers (Figure 4B). In line with these data, around twice as
many Ki67-positive cells were detectable at 38 hr and 48 hr after
PH in shMKK4 livers compared to shNC livers (Figures 4C and
4D). Consistent with published data (Sakamoto et al., 1999),
we only detected a very low number of apoptotic cells in regen-
erating livers and no difference was detected between regener-
ating shMKK4 livers and shNC livers (Figure S4A). To address
whether earlier cell-cycle entry and faster cell-cycle progression
in shMKK4-expressing hepatocytes ultimately result in an
increased number of shMKK4-expressing hepatocytes after
PH, we codelivered an MKK4-shRNA or a noncoding shRNA
together with GFP into wild-type mouse livers and subjected
these livers to PH. Strikingly, when the number of GFP-positive
hepatocytes was quantified 72 hr after hepatectomy, we
detected nearly two-fold more GFP-positive hepatocytes in the
shMKK4 transfected livers than in the shNC transfected liversCell 153, 389–401, April 11, 2013 ª2013 Elsevier Inc. 393
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Figure 3. Functional Analyses Reveal
Increased Regenerative Capacity of Hepa-
tocytes with Stable MKK4 Knockdown
(A) Knockdown test by western blot analysis using
whole-cell extracts of mouse livers repopulated
with two independent MKK4-shRNAs (FAHIG-
shMKK4-A and FAHIG-shMKK4-B) or a noncoding
shRNA (FAHIG-shNC). Tubulin serves as a loading
control (n = 4).
(B) Immunofluorescence analysis of MKK4
expression in mouse livers repopulated with two
independent MKK4-shRNAs (see A) or a non-
coding shRNA (shRNA-NC) (n = 4) (200 3 magni-
fication).
(C) Schematic representation of an in vivo com-
petition assay to determine the regenerative ca-
pacity of shNC-expressing hepatocytes compared
to shMKK4-expressing hepatocytes. Efficient liver
repopulation requires stable transposon delivery
(FAHIG vector, see Figure 1A) into a minimum
amount of FAH-deficient hepatocytes (left panel).
Undercutting the required minimum amount of
primary in vivo-transfected hepatocytes should
impede a successful liver regeneration and lead to
death due to liver failure when a noncoding shRNA
is delivered (middle panel, p/T-FAHIG-shNC).
Increased regenerative capacity by MKK4 sup-
pression should rescue successful liver re-
population (right panel, p/T-FAHIG-shMKK4).
(D) Survival analysis (Kaplan Meier format) of
mice injected with dilutions of p/T-FAHIG-NC, p/T-
FAHIG-shMKK4-A, and p/T-FAHIG-shMKK4-B.
ShMKK4 mediates a strong survival advantage
(n = 5 per group). Statistical significance was
calculated using the log rank test.
(E) GFP imaging of explanted mouse livers
reveals enhanced clonal expansion (repopulation)
of hepatocytes stably expressing shMKK4
compared to hepatocytes expressing shNC (day
20 after injection of 2.5 mg of the indicated plasmid). Two representative photographs are shown for each group (n = 5).
(F) Quantification of GFP-positive liver surface (corresponding to E) by GSA-ImageAnalyser reveals a significanty higher GFP-positive liver surface in livers of
p/T-FAHIG-shMKK4-injected mice compared to the control (data are presented as mean ± SEM). Statistical significance was calculated using Student’s t test.
See also Figure S3.(Figure S4B), thus demonstrating that MKK4 knockdown
results in an increased number of regenerated hepatocytes after
partial hepatectomy.
MKK4 Knockdown Increases the Robustness of
Hepatocytes In Vivo and In Vitro
Our data thus far showed increased hepatocyte proliferation and
regeneration upon MKK4 knockdown in two mouse models of
liver regeneration, the FAH/ model of liver repopulation and
the partial hepatectomy model. To ultimately probe the potential
of MKK4 inhibition as a strategy to increase liver regeneration in
liver disease, we next subjected mice with stable intrahepatic
expression of MKK4- or noncoding shRNAs to a treatment with
CD95 (FAS)-activating antibodies (Figure 5A), a well-established
mousemodel of acute liver failure (ALF) (Ogasawara et al., 1993).
Interestingly, MKK4 silencing not only increased compensatory
hepatocyte proliferation in this setting (data not shown) but
also enhanced the robustness of hepatocytes, as reflected by
a significantly decreased number of apoptotic hepatocytes394 Cell 153, 389–401, April 11, 2013 ª2013 Elsevier Inc.upon the induction of liver failure (Figures 5B and 5C). Impor-
tantly, decreased numbers of apoptotic cells in MKK4-shRNA-
expressing livers resulted in an increased long-term survival of
mice after induction of liver failure (Figure 5D).
Over the past couple of years strategies to isolate and trans-
plant human hepatocytes into diseased livers have been
advanced and already entered the clinic (Chistiakov, 2012).
Because our data showed that MKK4 suppression may also
increase the robustness of hepatocytes, we next wanted to
explore whether MKK4 inhibition may represent a strategy to
increase the efficiency of hepatocyte culture, transplantation,
and engraftment. Primary hepatocytes were isolated from
mouse livers stably expressing either MKK4-shRNAs or noncod-
ing shRNAs and taken into primary culture. Compared to shNC-
expressing hepatocytes, we found that shMKK4-expressing
hepatocytes showed increased survival in culture and, even after
prolonged in vitro culture, could be replated (Figure 5E) or trans-
planted into FAH/ mice, where they efficiently repopulated
the liver (Figure 5F). Therefore, MKK4 may also represent a
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Cell-Cycle Entry and Increases the Amount of Proliferating
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(A) Schematic representation of cell cycle and proliferation index time-course
analysis after partial hepatectomy of repopulated mouse livers stably ex-
pressing shNC or shMKK4.
(B) Western blot analyses for cyclin A and E (nuclear extracts from repopu-
lated mouse livers at the indicated time point) indicate an earlier cell-cycle
entry and faster cell-cycle progression of shMKK4-expressing mouse
livers (n = 3).
(C) Representative photographs of Ki67 immunostained liver sections (200 3
magnification) at different time points after partial hepatectomy show
increased hepatocyte proliferation after partial hepatectomy in shMKK4-ex-
pressing livers compared to shNC livers (n = 5 per group).promising target to improve hepatocyte transplantation or to in-
crease survival of primary human hepatocytes—for example,
within bioartificial liver devices.
Because increased proliferation and apoptosis resistance are
also hallmarks of malignant growth, we next sought to address
the risk of promoting tumorigenesis by MKK4 suppression.
Mice with stable intrahepatic MKK4 knockdown were monitored
for liver tumor development for 12 months; however, none of the
mice developed GFP-positive, shMKK4-expressing tumors (Fig-
ures S5A and S5B). In line with published reports on the FAH/
model (Grompe et al., 1995), only few GFP-negative background
tumors arose independently of the expressed shRNA (Fig-
ure S5B). Nevertheless, to further characterize potential
protumorigenic effects upon MKK4 inhibition, we analyzed the
tumorigenicity of a nontumorigenic hepatocyte cell line (AML12)
and immortalized liver progenitor cells (BNL CL.2 cells) after
RNAi-mediated MKK4 knockdown. However, while in both cell
lines RNAi-mediated knockdown of the well-established PTEN
tumor suppressor and subsequent subcutaneous cell transplan-
tation on nude mice readily induced oncogenic transformation
and tumor growth, no tumor growth was observed when MKK4
was inhibited (Figures S5C and S5D). We also found that
PTEN knockdown strongly accelerated tumor growth when fully
transformed, tumorigenic BNL 1NG A.2 cells were transplanted
on nude mice; however, compared to shNC-expressing cells,
there was no acceleration of tumor growth when MKK4 was
silenced (Figure S5E). Taken together, our data suggest that
suppression ofMKK4 is neither likely to be a strong tumor initiator
nor likely to be a strong tumor accelerator; however, our current
data cannot exclude the possibility that long-term MKK4 sup-
pression may promote tumorigenesis in some settings.
MKK4 Suppression in Hepatocytes Reduces Fibrosis
Development during Chronic Liver Damage
Chronic liver failure due to chronic hepatitis B or C virus infection
or alcohol abuse represents a major health problem with about
one million deaths per year (World Health Organization, 2011).
Chronic liver damage results in repetitive waves of hepatocyte
death and regeneration and ultimately, after the regenerative ca-
pacity of hepatocytes is exhausted, leads to the development of
liver fibrosis and liver failure (Hernandez-Gea and Friedman,
2011; Kisseleva and Brenner, 2011). In addition to the tested
mousemodels of liver repopulation, liver regeneration, and acute
liver failure, we therefore wanted to investigate whether suppres-
sion of MKK4 also increases liver regeneration during chronic
liver damage and thus may represent a therapeutic strategy in
chronic liver disease. Mice with stable intrahepatic expression
of MKK4-shRNAs or noncoding shRNAs were subjected to
long-term treatment with carbon tetrachloride (CCl4) (Figure 6A),
a widely used model for chronic liver damage and the develop-
ment of liver fibrosis (Pierce et al., 1987). Strikingly, MKK4
silencing led to a significant reduction of fibrosis development
(Figures 6B–6E), shown by sirius red and alpha smooth muscle(D) Quantification of Ki67 positive cells of immunostained liver sections
(corresponding to C) show increased hepatocyte proliferation after partial
hepatectomy in shMKK4-expressing livers compared to shNC livers (data are
represented as mean ± SD; n = 5 per group). See also Figure S4.
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Figure 5. Increased Robustness of Hepato-
cytes with Stable MKK4 Suppression
(A) Schematic outline for the induction of acute
liver failure by application of CD95-activating
antibody into mice repopulated from hepatocytes
either expressing shMKK4 or shNC.
(B) Histological analyses (H&E staining, right panel)
and TUNEL staining (left panel) for apoptotic cells
of mouse liver tissue with stable expression of the
indicated shRNA 9 hr after the induction of acute
liver failure as described in (A) (shown are repre-
sentative photographs; 2003magnification; n = 5
per group).
(C) Quantification of TUNEL-positive cells as
shown in (B) (data are represented as mean ± SD;
n = 5 per group). Statistical significance was
calculated using a Student’s t test.
(D) Survival analyses (Kaplan Meier format) of
mice with stable intrahepatic knockdown of
MKK4 or controls after triggering fulminant liver
failure as depicted in (A). Statistical significance
was calculated using a log rank test (n = 5 per
group).
(E) Phase-contrast microscopy of primary hepa-
tocyte cultures reveals increased long-term sur-
vival of isolated primary hepatocytes expressing
shMKK4 (left upper panel, d29 after plating)
compared to shNC-expressing hepatocytes (left
lower panel, d12 after plating). Hepatocytes
expressing shMKK4 can be efficiently replated
after trypsinization (shown is day 3 after replat-
ing, = d15 after initial plating). Experiments
were done in triplicates (isolation from indepen-
dently repopulated mice). Shown are representa-
tive photographs (100 3 magnification).
(F) Efficient liver repopulation and survival after
transplantation of shMKK4-expressing hepato-
cytes (kept 7 days in culture) into FAH/ mice.
Shown is a Kaplan Meier survival analysis of
mice after intrahepatic seeding of shMKK4
or shNC-expressing hepatocytes (500,000 hepa-
tocytes transplanted, n = 6 per group). Statistical
significance was calculated using a log rank test.
See also Figure S5.actin staining and hydroxyproline ELISA. Mechanistically, we
found significantly more proliferating hepatocytes in chronically
damaged, regenerating shMKK4-expressing mouse livers (Fig-
ures 6F and 6G). Interestingly, TUNEL staining also revealed
that mouse livers with reduced MKK4 suppression showed an
increased protection against apoptosis (Figures 6H and 6I),
thus suggesting that both increased hepatocyte proliferation
and decreased hepatocyte death may confine fibrosis develop-
ment in shMKK4-expressing livers.
MKK4 Suppression Increases Hepatocyte Regeneration
via Compensatory Upregulation of MKK7 and a JNK1-
Dependent Activation of ATF2 and ELK1
We were interested in exploring the molecular mechanism
whereby MKK4 knockdown increases the regenerative capacity396 Cell 153, 389–401, April 11, 2013 ª2013 Elsevier Inc.of hepatocytes. MKK4 is a dual-specific protein kinase that is
embedded in both major stress-kinase signaling pathways, the
p38 and the JNK pathway (Davis, 2000; Lee et al., 2002), and it
has been reported that p38 and JNK signaling act antagonisti-
cally on hepatocyte proliferation and liver regeneration (Wada
et al., 2008), whereas JNK signaling is believed to be proliferative
and p38 signaling antiproliferative. Recent data suggested
that JNK activation depends on activating signals from both
upstream kinases, MKK4 and MKK7; however, despite highly
efficient MKK4 knockdown (Figures 3A and 3B), we found a
strong increase of p-JNK levels in shMKK4-expressing
mouse livers by phoshoprotein antibody array profiling and
western blotting (Figures 7A and 7C). In support of the idea
that robust MKK7 expression levels alone may be sufficient
to induce p-JNK, we detected a strong induction of ASK-1, an
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Figure 6. Livers Harboring Stable MKK4
Knockdown Show Decreased Fibrosis
Development after Chronic Liver Damage
(A) Outline of the protocol applied to induce
chronic liver damage and fibrosis in repopulated
mouse livers.
(B) Sirius red staining for fibrotic scar tissue on
sections of indicated repopulated mouse livers
(n = 5 per group; representative sections are
shown, 200 3 magnification).
(C) Quantification of fibrotic liver area as shown in
(B) by ImageJ software (NIH). Statistical signifi-
cance was calculated using Student’s t test (data
are represented as mean ± SEM).
(D) Alpha smooth muscle actin staining as a
marker for activated hepatic stellate cells on liver
sections from repopulated livers with stable
expression of the indicated shRNA (n = 5 per
group; representative sections are shown, 200 3
magnification).
(E) Liver hydroxyproline content (corresponding to
hepatic collagen content) was determined after
chronic damage of mouse livers with stable
expression of either shMKK4 or shNC by hy-
droxyproline ELISA. Statistical significance was
calculated using Student’s t test (data are repre-
sented as mean ± SEM; n = 5).
(F) Representative photographs of Ki67 immuno-
stained liver sections (200 3 magnification) after
chronic liver damage in shMKK4-expressing livers
compared to shNC livers (n = 5 per group).
(G) Quantification of Ki67-positive cells (corre-
sponding to F) show increased hepatocyte prolif-
eration after liver injury in shMKK4-expressing
livers. Statistical significance was calculated using
student’s t test (data are represented as mean ±
SEM).
(H) Representative photographs of TUNEL-stained
liver sections (200 3 magnification) after chronic
damage of shMKK4 or shNC-repopulated livers
(n = 5 per group).
(I) Quantification of TUNEL-positive cells (corre-
sponding to H), shows a reduction in the number of
apoptotic cells in shMKK4-expressing livers (data
are represented as mean ± SEM; n = 5 per group).
Statistical significance was calculated using Stu-
dent’s t test.upstream kinase that can activate MKK7, as well as induction of
MKK7 itself (Figures 7A and 7B). In line with the idea that MKK4
suppression may alter the balance between p38 and JNK
signaling, we found decreased expression of p-p38 and its
downstream target p-HSP27 (Figures 7A, 7D, and 7E). However,
the AP1 transcription factor c-Jun, a classical downstream
target of JNK, was not found induced but rather decreased in
shMKK4-expressing livers (Figure 7F), thus suggesting that
MKK4 inhibition results in a more complex downstream signa-
ture of p38 and JNK target genes that probably also involves
altered cross-signaling between both pathways. As p-c-Jun
levels were decreased in mouse livers with stable MKK4 knock-
down, it is likely that other JNK downstream mediators may
convey the proregenerative signals in mouse livers with stable
MKK4 suppression. As possible candidates, we identified the
AP1 transcription factor ATF2 (Figures 7A and 7G) and the Etwenty-six (Ets) factor Elk1 (Figure 7A) as upregulated in
shMKK4-expressing livers.
To functionally probe which of the identified factors are crucial
for increased hepatocyte regeneration uponMKK4 inhibition, we
developed a unique transposon vector that allows for an efficient
coexpression of two shRNAs (Figures 7H and 7I). Efficient
shRNAs targeting MKK7, JNK1 (MAPK8), JNK2 (MAPK9),
ATF2, and ELK1were generated (Figures S6A–S6E) and codeliv-
ered individually with anMKK4-shRNA into FAH/mouse livers.
For the experiment, we stably transfected 1.25 mg of transposon
DNA, an amount that only allows liver repopulation from hepato-
cytes harboring MKK4 knockdown (Figures 3D and S3A).
Codelivery of an MKK4-shRNA together with a noncoding
shRNA (shNC) served as a control. NTBC was withdrawn to
induce liver repopulation and mice were harvested 15 days
after NTBC withdrawal to quantify the number of GFP-positiveCell 153, 389–401, April 11, 2013 ª2013 Elsevier Inc. 397
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Figure 7. MKK4 Suppression Increases
Hepatocyte Regeneration via Compensa-
tory Upregulation of MKK7 and a JNK1-
Dependent Activation of ATF2 and ELK1
(A) Whole-cell protein extracts from repopulated
mouse livers with stable expression of either
shMKK4 or shNC were isolated and analyzed by a
MAP kinase pathway antibody array. Shown are
the top increased or depleted factors. The heat
map key shows log2-fold changes. The hierarchi-
cal clustering relationship between sample profiles
is shown graphically as a dendrogram (left).
(B–G) Western blot analyses for the phosphoryla-
tion status of members of the p38 and JNK stress-
kinase signaling pathways (red-colored names
refer to proteins that are also shown in A; n = 3).
(H) Schematic representation of a transposable
element for stable intrahepatic gene expression of
FAH, the marker gene green fluorescent protein
(GFP), and two microRNA-based shRNAs.
(I) Determination of knockdown efficiency (western
blot) of the tandem transposon vector depicted in
(H). Knockdown analyses were carried out in 293T
cells cotransfected with Rb expression vectors
expressing the indicated shRNA combinations.
Tubulin serves as a loading control. Experiments
were done in triplicates and a representative
western blot is shown.
(J–O) GFP imaging of explanted mouse livers with
stable expression of the indicated combinations
of shRNAs (d15 after injection of 1.25 mg of the
indicated plasmid) to determine the number of
GFP-positive clones. Shown are representative
photographs, numbers denote the average num-
ber of GFP-positive clones with ± SD (data are
represented as mean ± SEM; n = 6, * indicates the
autofluorescent gallbladder).
(P) Schematic pathway representation indicating
the detected and functionally validated changes in
signal transduction uponMKK4 silencing. See also
Figures S6 and S7.liver-repopulating hepatocyte clones (Figures 7J–7O and S6F–
S6J). We found efficient liver repopulation when shMKK4 was
codelivered with a noncoding shRNAwith more than 300macro-
scopically visible GFP-positive clones already being visible at
this time point. In strong contrast, liver repopulation was signifi-
cantly reduced (only 20 GFP-positive clones) when shMKK4was
codelivered with an shRNA-targeting MKK7, which we had
found to be compensatorily upregulated in hepatocytes with
MKK4 knockdown (Figure 7B). MKK7 is known to signal to398 Cell 153, 389–401, April 11, 2013 ª2013 Elsevier Inc.JNK1 as well as JNK2; however, we
found that only JNK1 inhibition, but not
JNK2 inhibition, abolishes the prorege-
nerative effects of MKK4 knockdown,
whereas JNK2 silencing was able to
even further enhance regeneration upon
MKK4 silencing (Figures 7J, 7L, 7M, and
S6G–S6H). Interestingly, RNAi-mediated
knockdown of two independent down-
stream factors of JNK1, the AP1 factorATF2 and the Ets factor ELK1, each greatly decrease the regen-
erative capacity of MKK4 knockdown hepatocytes (Figures 7N
and 7O). In further support of a crucial role of ELK1 in liver regen-
eration, we found that ELK1 knockout mice (Cesari et al., 2004)
show a markedly reduced hepatocyte proliferation upon partial
hepatectomy (Figure S7).
Overall, our functional genetic data show that induction
of MKK7 and a JNK1-dependent activation of the AP1 transcrip-
tion factor ATF2 and the Ets factor ELK-1 are crucial for the
increased regenerative capacity of hepatocytes upon MKK4
inhibition.
DISCUSSION
This study describes a direct in vivo RNAi screen for gene targets
that can be exploited to increase the endogenous regenerative
capacity of hepatocytes. In contrast to other in vivo RNAi
screens that rely on the ex vivo transduction of target cells with
shRNA pools and subsequent transplantation of these cells
into mice (Zender et al., 2008; Zuber et al., 2011), this system
permits direct in vivo screening, and target cells for shRNA
expression are never taken out of their natural tissue microenvi-
ronment. Besides future use for genome-wide shRNA screens, it
is also suited for individually analyzing candidate genes,
because mice with stable and liver-specific knockdown pheno-
types for any desired target gene can be generated within
2 months.
We identify the dual-specific kinase MKK4 as a master regu-
lator of liver regeneration. MKK4 represents a dual-specific pro-
tein kinase that is essential for liver organogenesis (Ganiatsas
et al., 1998). Embryonic mouse livers of MKK4 knockout mice
contain high numbers of highly proliferating embryonic hepato-
cytes (hepatoblasts) but die because these cells cannot differen-
tiate into hepatocytes (Ganiatsas et al., 1998). We show that
MKK4 inhibition in adult hepatocytes greatly enhances their
proliferative and regenerative potential, but notably, and in
contrast to embryonic livers, the regeneration process stops
after liver repopulation has been completed. Therefore, signaling
pathways controlling proliferation and growth during embryonic
development may be revisited for the development of strategies
to induce or increase endogenous regeneration in adult somatic
tissues.
Despite the fact that hepatocytes harbor a nearly infinite ca-
pacity to proliferate under physiological conditions (Overturf
et al., 1997a), liver regeneration defects are often encountered
in chronic liver diseases. MKK4 inhibition could mobilize regen-
erative reserves of hepatocytes under liver damage and showed
robust therapeutic efficacy in mouse models of acute and
chronic liver failure. Interestingly, MKK4 silencing resulted in
reduced fibrosis development in the carbon tetrachloride
(CCl4) model, a well-established mouse model for chronic liver
damage and fibrosis induction (Pierce et al., 1987). Liver
fibrogenesis is mediated by a heterogenous population of profi-
brogenic myofibroblasts, the majority originating from hepatic
stellate cells, and it was shown that the activation of hepatic
stellate cells represents a critical event in fibrosis, because these
cells become the primary source of extracellular matrix in injured
livers (Hernandez-Gea and Friedman, 2011). While current
therapeutic strategies to curtail fibrosis and cirrhosis develop-
ment and progression mainly focus on targeting profibrogenic
cytokines and nonparenchymal liver cells such as activated
myofibroblasts (Kisseleva and Brenner, 2011), our data suggest
that hepatocyte-intrinsic gene targets may also be exploited to
confine fibrosis development.
We found that MKK4 inhibition results in a faster cell-cycle
entry and progression of hepatocytes during liver regeneration.
Different phases of liver regeneration have been defined andthe priming phase describes a critical and rate-limiting step
during liver regeneration, where hepatocytes in responses to
extrinsic stimuli leave the G0 phase and enter the G1 phase of
the cell cycle (Taub, 2004). Against the background of the iden-
tified accelerated cell-cycle entry our data support a model
where MKK4 inhibition may render hepatocytes more sensitive
to external priming phase-inducing stimuli, or it may even be
speculated that hepatocytes with MKK4 knockdown reside in
a ‘‘permanent priming phase’’ and can therefore quickly enter
the cell cycle and give rise to new hepatocytes.
Interestingly, it was recently shown that regenerating livers are
protected against Fas-induced apoptosis (Desbarats and New-
ell, 2000). Our data show that resting, nonregenerating livers
with MKK4 silencing already show increased resistance against
Fas-induced apoptosis, suggesting that a constitutive priming
phase might mediate the increased robustness.
Increased proliferation and apoptosis resistance are hallmarks
of malignant cell growth. We followed mice with stable intrahe-
patic knockdown for 12 months, to monitor any tumor develop-
ment; however, no tumors with MKK4-shRNA expression were
observed during this period, suggesting that loss of MKK4 is
unlikely to be a strong tumor-initiating event. Furthermore, clas-
sical tumorigenicity assays revealed that MKK4 knockdown was
neither able to malignantly transform nontumorigenic murine
liver cells, nor able to accelerate tumor growth of readily trans-
formed murine liver carcinoma cells. Nevertheless, our data do
not exclude the possibility that reduced MKK4 expression or
impaired MKK4 function due to mutations may contribute to tu-
mor progression in some settings. Our screen was based on the
assumption that proliferation control during tissue regeneration
and tumorigenesis depend on overlapping signaling pathways
and the screened shRNA library contained shRNAs against
gene targets that were found embedded in focal genomic dele-
tions in human hepatocellular carcinoma (Zender et al., 2008).
In our data set of 100 human hepatocellular carcinomas
analyzed by high-resolution array-based comparative genomic
hybridization, we found one tumor with a focal genomic deletion
encompassingMKK4 (Zender et al., 2008). Also, MKK4 has been
discussed as a tumor suppressor gene in ovarian and lung can-
cer (Yeasmin et al., 2011; Ahn et al., 2011). While collectively
these data suggest that MKK4 suppression or altered function
may contribute to tumor progression in some settings, we
believe that a therapeutic window for transient and intermittent
pharmacological MKK4 inhibition to increase liver regeneration
exists.
The only curative and definitive treatment option for fulminant
acute liver failure and end-stage chronic liver failure is liver trans-
plantation; however, the number of available donor livers is
limited. Our data show that MKK4 inhibition increases the regen-
erative capacity of hepatocytes in settings of acute and chronic
liver damage, and pharmacological MKK4 inhibitors may there-
fore represent a strategy for the treatment of patients with acute
or chronic liver disease.
Taken together, the herein outlined strategies describe an
approach to discover gene targets that can be exploited to in-
crease the regenerative capacity of hepatocytes. Against the
background of our current knowledge of signaling pathways
that control hepatocyte proliferation, a hypothesis-drivenCell 153, 389–401, April 11, 2013 ª2013 Elsevier Inc. 399
selection of MKK4 as a potential target to increase liver regener-
ation would have been unlikely. We therefore believe that our
study once more emphasizes the power of unbiased functional
genetic screens to identify new gene targets in different biolog-
ical systems. Specifically, our study serves as a blueprint for
how RNAi-based functional genetic screens can be used to
identify gene targets to increase the endogenous regenerative
capacity of tissues.
EXPERIMENTAL PROCEDURES
Mice and Hydrodynamic Injection
FAH knockout mice have been generated by Dr. Markus Grompe (Grompe
et al., 1995) (Oregon Health Sciences University) and were obtained in a
C57BL/6 background from Dr. Arndt Vogel (Hannover Medical School). Mice
were kept on the drug NTBC (2-[2-nitro-4-{trifluoromethyl}benzoyl]cyclo-
hexane-1,3-dione) at 19.2 mg per 1 liter drinking water to prevent liver failure.
NMRI nu/nu mice for subcutaneous tumor studies were purchased from Har-
lan laboratories (Rossdorf, Germany). ELK knockout mice were generated and
kindly provided by Dr. Alfred Nordheim (Cesari et al., 2004). All mice were
maintained under pathogen-free conditions in accordance with the institu-
tional guidelines of the Helmholtz Centre for Infection Research and Hannover
Medical School. All animal experiments have been approved by the German
legal authorities.
Vectors for hydrodynamic tail vein injection (Liu et al., 1999) were prepared
using the QIAGEN EndoFree Maxi Kit (QIAGEN). For transposon-mediated
gene transfer, animals received a 5:1 molar ratio of transposon to transpo-
sase-encoding plasmid (25 mg total DNA, unless otherwise stated). DNA was
suspended in saline solution at a final volume of 10% of the animal’s body
weight and injected via the tail vein in less than 10 s. For transient, intrahepatic
expression of luciferase, 5 mg of pcDNA-Luc or the pBlueSK control vector was
delivered intrahepatically by hydrodynamic tail vein injection. Progression of
liver repopulation was monitored at different time points by whole-liver
GFP imaging using a Hamamatsu Imaging system. The GFP-positive liver sur-
face area was calculated using the software GSA-ImageAnalyser (GSA).
Whole-body bioluminescence imaging was done as described before (Xue
et al., 2007). Luciferase imaging was done in living mice using the IVIS
in vivo imaging system (Xenogen). Mice were intraperitoneally injected with
D-luciferin (SynchemOHG) (7.5 mg/g body weight), anesthetized with Isoflur-
ane (Albrecht), and analyzed 10 min after injection.
Two-Thirds Hepatectomy
Two-thirds (partial) hepatectomy was performed on repopulated FAH/mice
as described before (Mitchell and Willenbring, 2008). The median, right, and
caudate liver lobes were surgically removed while mice were under general
anesthesia.
Carbon Tetrachloride (CCl4) Treatment
CCl4 treatment was performed for a 6 week period by intraperitoneal injection
twice per week. The mice received 0.25 ml/kg body weight CCl4 (Sigma)
dissolved in sunflower oil (Sigma).
A detailed description of all experimental procedures is provided in the
Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
seven figures and can be found with this article online at http://dx.doi.org/
10.1016/j.cell.2013.03.026.
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